Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer.
Selection of cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance (MDR) genes, which encode the cell surface P-glycoproteins, as a result of gene amplification, transcriptional activation, or mRNA stabilization. The LMD1 and LMD4 cell lines were established after the transfer into mouse L cells of two independent yeast artificial chromosome clones containing 300 and 850 kb, respectively, of the human MDR locus. The human MDR1/PGY1 gene, but not the endogenous mouse mdr1a and mdr1b genes, was overexpressed as a result of gene amplification and transcriptional activation in various sublines of LMD1 and LMD4 cells selected for resistance to vincristine. Then we asked why human MDR1/PGY1 gene, but not mouse relevant gene, was expressed. Determination of the methylation status of cytosine residues at Msp I/Hap II cleavage sites (CCGG) in the promoter regions of human MDR1/PGY1 and mouse mdr1a revealed hypomethylation and hypermethylation of the human and mouse genes, respectively in LMD1, LMD4, and their vincristine-resistant derivatives. Various vincristine-resistant sublines were also established after exposure of LMD1 cells for 48 h to 5-aza-2'-deoxycytidine, an inhibitor of DNA methyltransferase. These sublines exhibited overexpression of mouse mdr1a and mdr1b, but not of human MDR1/PGY1, as well as hypomethylation of the mouse mdr1a promoter region. Thus, the selective expression of human or mouse MDR genes in this cell system appears to be related to the methylation status of the respective gene promoter regions.
Kusaba
H
H
Department of Biochemistry, Kyushu University School of Medicine, Fukuoka, Japan.
Nakayama
M
M
Harada
T
T
Torigoe
K
K
Green
E D
ED
Scherer
S W
SW
Kohno
K
K
Kuwano
M
M
Wada
M
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis* / Q000235:genetics; D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000633:toxicity; D002470:Cell Survival / Q000187:drug effects; D018244:Chromosomes, Artificial, Yeast; D002999:Clone Cells; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D000077209:Decitabine; D015226:Dinucleoside Phosphates / Q000032:analysis; D018432:Drug Resistance, Multiple / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000633:toxicity; D005091:Exons; D005784:Gene Amplification; D005819:Genetic Markers; D006801:Humans; D007739:L Cells; D051379:Mice; D011401:Promoter Regions, Genetic; D011994:Recombinant Proteins / Q000096:biosynthesis; D015183:Restriction Mapping; D015533:Transcriptional Activation; D014162:Transfection / Q000379:methods; D014410:Tumor Stem Cell Assay; D014750:Vincristine / Q000633:toxicity
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001374:Azacitidine; D015254:DNA Modification Methylases; D000077209:Decitabine; D015226:Dinucleoside Phosphates; D004791:Enzyme Inhibitors; D005819:Genetic Markers; D011994:Recombinant Proteins; D014750:Vincristine; C015772:CpG dinucleotide